Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production

Journal of Clinical Investigation

Volumn 125, Issue 10, 2015, Pages 3819-3830

  Guo, Yanhong ^a   Fan, Yanbo ^a   Zhang, Jifeng ^a   Lomberk, Gwen A ^b   Zhou, Zhou ^c   Sun, Lijie ^a,d   Mathison, Angela J ^b   Garcia Barrio, Minerva T ^e   Zhang, J ^a   Zeng, Lixia ^f   Li, Lei ^d,f   Pennathur, Subramaniam ^f   Willer, Cristen J ^a   Rader, Daniel J ^g   Urrutia, Raul ^b   Chen, Y Eugene ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^d PEKING UNIVERSITY THIRD HOSPITAL   (China)

^e MOREHOUSE SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KRUPPEL LIKE FACTOR 4; PERHEXILINE; CHOLESTEROL; HYBRID PROTEIN; KLF14 PROTEIN, HUMAN; KLF14 PROTEIN, MOUSE; KRUPPEL LIKE FACTOR; LEPTIN; MESSENGER RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRANSCRIPTION FACTOR SP;

ADULT; ANGINA PECTORIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DYSLIPIDEMIA; EXPERIMENTAL MODEL; GENE INACTIVATION; HEART FAILURE; HUMAN; HUMAN CELL; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; UPREGULATION; AGONISTS; ANIMAL; ATHEROGENIC DIET; BIOSYNTHESIS; BLOOD; C57BL MOUSE; DEFICIENCY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE THERAPY; GENE VECTOR; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HEP-G2 CELL LINE; HYPERLIPOPROTEINEMIA TYPE II; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; PRECLINICAL STUDY; THERAPEUTIC USE;

ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CHOLESTEROL; CHOLESTEROL, HDL; DIET, ATHEROGENIC; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION; GENETIC THERAPY; GENETIC VECTORS; GENOME-WIDE ASSOCIATION STUDY; HEP G2 CELLS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LEPTIN; LIVER; MICE; MICE, INBRED C57BL; MICE, OBESE; PERHEXILINE; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; SP TRANSCRIPTION FACTORS; STEROL REGULATORY ELEMENT BINDING PROTEINS;

EID: 84943222952     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI79048     Document Type: Article

References (59)

1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62(5):707-714.
2. Gordon DJ, et al. Bangdiwala S, and Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79(1):8-15.
3. McQueen MJ, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a casecontrol study. Lancet. 2008;372(9634):224-233.
4. Yusuf S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): casecontrol study. Lancet. 2004;364(9438):937-952.
5. Boekholdt SM, et al. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statintreated patients: a meta-analysis. Circulation. 2013;128(14):1504-1512.
6. Khera AV, et al. Cholesterol efflux capacity, highdensity lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364(2):127-135.
7. Hafiane A, Jabor B, Ruel I, Ling J, Genest J. Highdensity lipoprotein mediated cellular cholesterol efflux in acute coronary syndromes. Am J Cardiol. 2014;113(2):249-255.
8. Rohatgi A, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371(25):2383-2393.
9. Digby JE, Ruparelia N, Choudhury RP. Niacin in cardiovascular disease: recent preclinical and clinical developments. Arterioscler Thromb Vasc Biol. 2012;32(3):582-588.
10. Kappelle PJ, van Tol A, Wolffenbuttel BH, Dullaart RP. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion. Cardiovasc Ther. 2011;29(6):e89-e99.
11. Goldenberg I, Goldbourt U, Boyko V, Behar S, Reicher-Reiss H, BIP Study Group. Relation between on-treatment increments in serum highdensity lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial). Am J Cardiol. 2006;97(4):466-471.
12. Jahagirdar R, et al. A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice. Atherosclerosis. 2014;236(1):91-100.
13. McLure KG, et al. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. PLoS One. 2013;8(12):e83190.
14. Picaud S, et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc Natl Acad Sci U S A. 2013;110(49):19754-19759.
15. [No authors listed]. Rvx 208. Drugs R D. 2011;11(2):207-213.
16. Nicholls SJ, et al. Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statintreated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol. 2011;57(9):1111-1119.
17. Teslovich TM, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466(7307):707-713.
18. Chen X, et al. Genome-wide association study validation identifies novel loci for atherosclerotic cardiovascular disease. J Thromb Haemost. 2012;10(8):1508-1514.
19. Chasman DI, et al. Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet. 2009;5(11):e1000730.
20. de Assuncao TM, et al. New role for Kruppel-like factor 14 as a transcriptional activator involved in the generation of signaling lipids. J Biol Chem. 2014;289(22):15798-15809.
21. Huang P, et al. Association of the KLF14 rs4731702 SNP and serum lipid levels in the Guangxi Mulao and Han populations. Biomed Res Int. 2013;2013:231515.
22. McConnell BB, Yang VW. Mammalian Kruppellike factors in health and diseases. Physiol Rev. 2010;90(4):1337-1381.
23. Chen G, et al. Genome-wide association study identifies novel loci association with fasting insulin and insulin resistance in African Americans. Hum Mol Genet. 2012;21(20):4530-4536.
24. Ohshige T, et al. Association of new loci identified in European genome-wide association studies with susceptibility to type 2 diabetes in the Japanese. PLoS One. 2011;6(10):e26911.
25. Rees SD, et al. Replication of 13 genome-wide association (GWA)-validated risk variants for type 2 diabetes in Pakistani populations. Diabetologia. 2011;54(6):1368-1374.
26. Small KS, et al. Identification of an imprinted master trans regulator at the KLF14 locus related to multiple metabolic phenotypes. Nat Genet. 2011;43(6):561-564.
27. Stacey SN, et al. New common variants affecting susceptibility to basal cell carcinoma. Nat Genet. 2009;41(8):909-914.
28. Steegenga WT, et al. Genome-wide agerelated changes in DNA methylation and gene expression in human PBMCs. Age (Dordr). 2014;36(3):9648.
29. Sarmento OF, et al. A novel role for KLF14 in T regulatory cell differentiation. Cell Mol Gastroenterol Hepatol. 2015;1(2):188-202 e4.
30. Shimomura I, Bashmakov Y, Horton JD. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem. 1999;274(42):30028-30032.
31. Mei M, et al. Inflammatory stress exacerbates ectopic lipid deposition in C57BL/6J mice. Lipids Health Dis. 2011;10:110.
32. Hellerstein M, Turner S. Reverse cholesterol transport fluxes. Curr Opin Lipidol. 2014;25(1):40-47.
33. Glickman RM, Green PH, Lees RS, Tall A. Apoprotein A-I synthesis in normal intestinal mucosa and in Tangier disease. N Engl J Med. 1978;299(26):1424-1427.
34. Acharjee S, Roe MT, Amsterdam EA, Holmes DN, Boden WE. Relation of admission high-density lipoprotein cholesterol level and in-hospital mortality in patients with acute non-ST segment elevation myocardial infarction (from the National Cardiovascular Data Registry). Am J Cardiol. 2013;112(8):1057-1062.
35. Sachdeva A, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J. 2009;157(1):111-117.
36. Zhao XQ, Brown BG. ApoA-I(Milano)/phospholipid complex: clinical implications of dose-response studies in rabbit atherosclerosis with intravascular ultrasound and magnetic resonance imaging. J Am Coll Cardiol. 2008;51(11):1110-1111.
37. Nissen SE, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290(17):2292-2300.
38. Tardif JC, et al. Effects of reconstituted highdensity lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007;297(15):1675-1682.
39. Diditchenko S, et al. Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. Arterioscler Thromb Vasc Biol. 2013;33(9):2202-2211.
40. Gille A, Easton R, D'Andrea D, Wright SD, Shear CL. CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects. Arterioscler Thromb Vasc Biol. 2014;34(9):2106-2114.
41. Waksman R, et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated highdensity lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol. 2010;55(24):2727-2735.
42. Parolini C, et al. Apolipoprotein A-I and the molecular variant apoA-I(Milano): evaluation of the antiatherogenic effects in knock-in mouse model. Atherosclerosis. 2005;183(2):222-229.
43. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E, Rader DJ. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation. 1999;100(17):1816-1822.
44. Benoit P, et al. Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. Circulation. 1999;99(1):105-110.
45. Rader DJ, Hovingh GK. HDL and cardiovascular disease. Lancet. 2014;384(9943):618-625.
46. Zhang H, et al. Mouse KLF11 regulates hepatic lipid metabolism. J Hepatol. 2013;58(4):763-770.
47. Ridker PM, Pare G, Parker AN, Zee RY, Miletich JP, Chasman DI. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ Cardiovasc Genet. 2009;2(1):26-33.
48. Johannsen TH, et al. Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease. J Clin Endocrinol Metab. 2009;94(4):1264-1273.
49. Frikke-Schmidt R, et al. Association of loss-offunction mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA. 2008;299(21):2524-2532.
50. Kong A, et al. Parental origin of sequence variants associated with complex diseases. Nature. 2009;462(7275):868-874.
51. Ikram H, Maslowski AH. Unstable angina and perhexilene maleate. N Z Med J. 1981;94(692):236-237.
52. Ashrafian H, Horowitz JD, Frenneaux MP. Perhexiline. Cardiovasc Drug Rev. 2007;25(1):76-97.
53. Phan TT, et al. Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope. Eur J Heart Fail. 2009;11(9):881-886.
54. Bansal M, Chan J, Leano R, Pillans P, Horowitz J, Marwick TH. Effects of perhexiline on myocardial deformation in patients with ischaemic left ventricular dysfunction. Int J Cardiol. 2010;139(2):107-112.
55. Drury NE, et al. Relationship between plasma, atrial and ventricular perhexiline concentrations in humans: insights into factors affecting myocardial uptake. Br J Clin Pharmacol. 2014;77(5):789-795.
56. Zarain-Herzberg A, Rupp H. Therapeutic potential of CPT I inhibitors: cardiac gene transcription as a target. Expert Opin Investig Drugs. 2002;11(3):345-356.
57. Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371(1):32-41.
58. Fan Y, Guo Y, Hamblin M, Chang L, Zhang J, Chen YE. Inhibition of gluconeogenic genes by calcium-regulated heat-stable protein 1 via repression of peroxisome proliferatoractivated receptor alpha. J Biol Chem. 2011;286(47):40584-40594.
59. Chang L, et al. Loss of perivascular adipose tissue on peroxisome proliferator-activated receptor-gamma deletion in smooth muscle cells impairs intravascular thermoregulation and enhances atherosclerosis. Circulation. 2012;126(9):1067-1078.